Navigation Links
U.S. Bests Canada, Europe in Drug Approvals
Date:5/16/2012

WEDNESDAY, May 16 (HealthDay News) -- New drugs are approved faster in the United States than in Europe and Canada, new research shows.

The findings counter a common belief that the drug-approval process by the U.S. Food and Drug Administration is especially slow, according to Yale University School of Medicine researchers.

The study authors reviewed drug-approval decisions made between 2001 and 2010 by the FDA, Health Canada (the Canadian drug regulator), and the European Medicines Agency (EMA). The latter agencies were chosen for comparison with the FDA because they face similar pressures to approve new drugs quickly while ensuring patient safety, the researchers said.

"Among the subsample of drugs approved for all three regulators, the FDA's reviews were over three months faster than those of the EMA or Health Canada," study leader Nicholas Downing, a second-year medical student, said in a university news release.

"The total review time at the FDA was faster than EMA, despite the FDA's far higher proportion of applications requiring multiple regulatory reviews," he added.

The study also revealed that most new drug therapies were first approved for use in the United States.

"Examining novel drugs approved in multiple markets, we found that 64 percent of medicines approved in both the U.S. and in Europe were approved for U.S. patients first, and 86 percent of medicines approved in both the U.S. and Canada were also approved first in the U.S.," Downing said.

The study was published online May 16 in the New England Journal of Medicine.

More information

The FDA explains how it approves drugs.

-- Robert Preidt

SOURCE: Yale University, news release, May 16, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. ‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail!
2. Brown Rice Bests White for Diabetes Prevention
3. TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List
4. Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
5. Grays Anatomy for Students, worlds bestselling anatomy textbooks, now available on iPad
6. Experimental Psoriasis Drug Bests Older Treatment
7. New procedure bests standard of care for fixing damaged cartilage
8. Report: For every 1 homeless person in Canada, another 23 live in inadequate housing
9. End-of-Life Care Differs Between U.S., Canada, Study Finds
10. New High Purity Immunoglobulin Enters Phase III in Europe and the US
11. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U.S. Bests Canada, Europe in Drug Approvals
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... it will co-exhibit with technology partners LG Business Solutions at ATARC Federal ... Center in Washington D.C., will provide education and examination into the mobility tools ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Columbia, March 27, 2017  Sophiris Bio Inc. ... "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin ... diseases, today reported fourth quarter and full year ... Key Corporate Highlights: ... Prostate Cancer. During 2016, the Company reported successful ...
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... 2017  iCAD (Nasdaq: ICAD), an industry-leading provider ... therapy for the early identification and treatment of ... Premarket Approval (PMA) from the U.S. Food and ... first-of-its-kind, concurrent-read computer aided detection solution for digital ... available on the PowerLook® Breast Health Solutions platform.  ...
Breaking Medicine Technology: